Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic HCT
NCT05922761Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belumosudil in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Dana-Farber Cancer Institute. Started May 2024; status: recruiting.
02
Drugs
belumosudil
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT05922761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922761.